Advancements in Safe and Effective Injectable Treatment for Asthma
There are currently several injectable biologic treatments approved for use in severe asthma. The treatments are selected for patients based on their specific factors. Pharmacists need to be well-versed in all biologic treatments available to ensure that patients are treated with the most appropriate agent. Following this CE, pharmacists will be able to use the knowledge acquired to analyze the treatment regimens of their current patient population and assist with clinical decision making.
Learning Objectives
Upon completion of this activity, the participant will be able to:
- Explain the role of monoclonal antibodies in the treatment of severe asthma.
- Differentiate between biologic treatments for severe asthma.
- Identify which patients benefit from these injectable therapies.
- Compare characteristics of injectable therapies to determine which biologic is right for the patient.
- Identify important points to counsel on for administration of each product, to ensure patient safety.
Presenter
Rebecca Williams, PharmD, is a PGY-1 community-Based Pharmacy Resident based in Massachusetts. She graduated from the Belmont University College of Pharmacy where she attained her PharmD in April 2021. During pharmacy school, she worked as a pharmacy intern for Walgreens in Nashville, TN.
Fellowship mentor: Matthew Machado, PharmD, Professor of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences
Registration Fee: This module is provided free of charge to all.
Release Date: May 27, 2022
Expiration Date: May 26, 2023
ACPE UAN: 0026-0000-22-006-H01-P | Knowledge
ACPE Topic Designator: Drug Therapy
Contact Hours: 1.0 (0.1 CEU)
Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Massachusetts College of Pharmacy and Health Sciences designates this activity for a total of 1.0 contact hour (0.1 CEU).
To receive credit, participants must complete pre and post-assessments, view the entire presentation, and evaluate the session. Participant credit will be reported to the CPE Monitor upon conclusion. Transcripts may be printed from the CPE Monitor.
The policy of Massachusetts College of Pharmacy and Health Sciences is ensuring balance, independence, objectivity, and scientific rigor in all of its educational activities. Any individuals involved in planning or content creation for a continuing education activity are required to disclose financial relationships with ineligible companies that have occurred within the last 24 months. The intent of the policy is to identify and mitigate potential conflicts of interest that may affect the activity. All clinical medicine recommendations must be based on evidence accepted within the medical profession.
Rebecca Williams does not hold relevant financial relationships with ineligible companies.
Fellowship mentor, Matthew Machado, does not hold relevant financial relationships with ineligible companies.
Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies related to the content of this presentation.
Massachusetts College of Pharmacy and Health Sciences will identify, review, and mitigate all conflicts of interest disclosed prior to delivery of an educational activity to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but provides participants with information that may be of potential importance when they are evaluating content.